Cox proportional hazards regression models were used to estimate hazard ratios (HRs) (95% CI) for the time-varying impact of depression on protocol-defined clinical outcomes with and without adjustment for demographic, trial-related, clinical, and behavioral variables.
We will extract data regarding patient demographics, trial methodology, intervention details and outcome data guided by the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT).
Baseline demographics, trial design, antiplatelet therapy use, concomitant GpIIb/IIIa inhibitor use, access site for PCI, and outcomes data were extracted from each trial.
A search of the literature was conducted to review RCTs in testicular cancer (TC) to assess demographic and trial reporting quality patterns over time.
Despite the process ambiguity, there were no significant differences (P > 0.05) between the group demographics, increasing trial robustness.
For the Phase I clinical trial, demographic data were compared among treatment group using Fisher's exact test for categorical factors and Kruskal-Wallis test for continuous factors.
Barriers and facilitators were similar across demographic groups and trial outcomes.
Eighteen baseline clinical, histological, biochemical and demographic variables (including trial and randomised treatment group) were considered appropriate for analysis as possible prognostic factors (Table 2).
Basic demographic and other trial related data were either supplied by the lead authors (or nominated deputies) or extracted from the original publication by an investigator (MB).
